DIADIA0.10%
SPYSPY0.21%
QQQQQQ0.36%
Trending
Top trending tickerONDSONDS8.35%
SLSSLS1.68%
AVAVAVAV33.45%
ENPHENPH11.56%
EOSEEOSE
RDWRDW8.72%
AMPXAMPX8.65%
ARDXARDX1.47%
ABVXABVX35.61%
IBRXIBRX1.31%
Top trending tickerONDSONDS8.35%
SLSSLS1.68%
AVAVAVAV33.45%
ENPHENPH11.56%
EOSEEOSE
RDWRDW8.72%
AMPXAMPX8.65%
ARDXARDX1.47%
ABVXABVX35.61%
IBRXIBRX1.31%

Feed

News

Sentiment

Earnings

Fundamentals

Info

homeSymbolZVRAnews
Exchange: NASDAQ·Updated 07:41 AM EDT
ZVRA logo

ZVRAZevra Therapeutics Inc

$14.00
$0.01
(0.07%)
Pre-Market
Prev Close $14.01
EarningsAug 11
Mkt Cap$799.24M
Vol11,601.00
News
all
press releases
Tamara A Favorito Expands Holdings With $51K Zevra Therapeutics Stock Options Acquisition
A notable acquisition unfolded on June 18, as Favorito, Director at Zevra Therapeutics (NASDAQ:ZVRA), reported the acquisition of stock options for 30,000 shares in an SEC filing. What Happened: A Form 4 filing from theread more...
Benzinga
News Placeholder
More News
News Placeholder
Corey M. Watton Seizes Opportunity: Acquires $51K Worth Of Zevra Therapeutics Stock Options
In a recent SEC filing, it was disclosed that Corey M. Watton, Board Member at Zevra Therapeutics (NASDAQ:ZVRA), made a noteworthy acquisition of company stock options on June 18,. What Happened: A Form 4 filing fromread more...
Benzinga
News Placeholder
A Noteworthy Decision By Thomas Anderson As Acquires $51K In Zevra Therapeutics Stock Options
In a new SEC filing on June 18, it was unveiled that Anderson, Director at Zevra Therapeutics (NASDAQ:ZVRA), acquired stock options for 30,000 shares. What Happened: Uncovered in a Form 4 filing on Thursday with theread more...
Benzinga
News Placeholder
Alicia Secor Takes A Bullish Stance, Acquiring $51K Worth Of Zevra Therapeutics Stock Options
A noteworthy insider acquisition was disclosed on June 18, as Secor, Board Member at Zevra Therapeutics (NASDAQ:ZVRA), reported the acquisition of stock options for 30,000 shares. What Happened: Uncovered in a Form 4read more...
Benzinga
News Placeholder
Douglas W Calder Makes Strategic Play: Invests $51K In Zevra Therapeutics Stock Options
In a new SEC filing on June 18, it was unveiled that Calder, Board Member at Zevra Therapeutics (NASDAQ:ZVRA), acquired stock options for 30,000 shares. What Happened: Calder, Board Member at Zevra Therapeutics,read more...
Benzinga
News Placeholder
Big News: Alvin Shih Adds $51K In Zevra Therapeutics Stock Options Io Portfolio
In a new SEC filing on June 18, it was unveiled that Shih, Board Member at Zevra Therapeutics (NASDAQ:ZVRA), acquired stock options for 30,000 shares. What Happened: In a recent Form 4 filing with the U.S. Securitiesread more...
Benzinga
News Placeholder
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?
Zevra Therapeutics shares saw a series of positive brokerage actions after the company asked the U.S. Food and Drug Administration to add a new patent for its Miplyffa drug to the Orange Book.
Stocktwits
News Placeholder
ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug
Zevra said in a statement that it has asked the U.S. Food and Drug Administration to add its new patent for its drug MIPLYFFA to its official list.
Stocktwits
News Placeholder
Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +184.36% and +15.51%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -29.46% and -15.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.